The ASCEND study was a large, international trial that aimed to assess the effects of avosentan on diabetic nephropathy. To the disappointment of the nephrology community who had anticipated that the trial would demonstrate beneficial effects of this treatment, ASCEND was terminated early owing to excessive rates of adverse events, such as congestive heart failure associated with avosentan use.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Mann, J. F. et al. Avosentan for overt diabetic nephropathy. J. Am. Soc. Nephrol. 21, 527–535 (2010).
Prasad, V. S., Palaniswamy, C. & Frishman, W. H. Endothelin as a clinical target in the treatment of systemic hypertension. Cardiol. Rev. 17, 181–191 (2009).
Galie, N. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Respir. J. 34, 1219–1263 (2009).
Sorokin, A. & Kohan, D. E. Physiology and pathology of endothelin-1 in renal mesangium. Am. J. Physiol. Renal Physiol. 285, F579–F589 (2003).
Dhaun, N., Goddard, J. & Webb, D. J. The endothelin system and its antagonism in chronic kidney disease. J. Am. Soc. Nephrol. 17, 943–955 (2006).
Sasser, J. M. et al. Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J. Am. Soc. Nephrol. 18, 143–154 (2007).
Sarafidis, P. A. & Lasaridis, A. N. Insulin resistance and endothelin: another pathway for renal injury in patients with the cardiometabolic syndrome? J. Cardiometab. Syndr. 3, 183–187 (2008).
Sarafidis, P. A. & Ruilope, L. M. Insulin resistance, hyperinsulinemia, and renal injury: mechanisms and implications. Am. J. Nephrol. 26, 232–244 (2006).
Jurgens, C. et al. The ETA-selective antagonist SPP301 reduces proteinuria in patients with diabetic nephropathy on top of high-dose AT1 receptor blockade. Kidney Blood Press. Res. 314(A) (2003).
Wenzel, R. R. et al. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J. Am. Soc. Nephrol. 20, 655–664 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Sarafidis, P., Lasaridis, A. Endothelin antagonism for diabetic nephropathy. Nat Rev Nephrol 6, 447–449 (2010). https://doi.org/10.1038/nrneph.2010.86
Issue date:
DOI: https://doi.org/10.1038/nrneph.2010.86
